Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Randomized phase II trial of patient-specific dendritic cell vaccines loaded with autologous tumor antigens versus autologous monocytes in patients with primary advanced ovarian cancer.
Authors
Robert O. Dillman
AIVITA Biomedical, Inc., Irvine, CA
Robert O. Dillman, Lisa Abaid, Candace Hsieh, Christopher Langford, Gabriel I. Nistor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Vaccines and Oncolytic Viruses
Clinical Trial Registration Number
NCT02033616
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr TPS10)
DOI
10.1200/JCO.2019.37.8_suppl.TPS10
Abstract #
TPS10
Poster Bd #
H3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Randomized phase 2 trial of personal dendritic cell (DC)-autologous tumor antigen (ATA) vaccines in newly diagnosed advanced ovary cancer.
First Author: Bradley Corr
Poster
2018 ASCO Annual Meeting
Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer.
First Author: William Rayford Gwin III
Poster
2014 ASCO Annual Meeting
Phase II study with immunotherapy with dendritic cells (DC) and intratumoral hiltonol in patients with advanced solid tumors.
First Author: José María López-Picazo
Poster
2013 ASCO Annual Meeting
Double-loaded mature dendritic cell (DC) therapy for non-HLA-restricted patients with advanced ovarian cancer: Final results of a clinical phase I study.
First Author: Marianne Imhof